SML2112
GSK8815
≥98% (HPLC)
别名:
8-((3S,4S,5R)-3-((4,4-二氟环己基)甲氧基)-5-甲氧哌啶-4-基氨基)-3-甲基-5-(5-甲基吡啶-3-基)-1,7-萘啶-2(1H)-one, 8-[[(3S,4S,5R)-3-[(4,4-二氟环己基)甲氧基]-5-甲氧基-4-哌啶基]氨基]-3-甲基-5-(5-甲基-3-吡啶基)-1,7-萘啶-2(1H)-酮
生化/生理作用
GSK8815是一种水溶性(326 μM)萘啶酮,在ATAD2/ATAD2B抑制研究中用作活性更高的非对映异构体GSK8814的阴性对照。与GSK8814相比,GSK8815在基于细胞的测定中无效,并且在无细胞结合测定中对ATAD2和ATAD2B布罗莫结构域(BD)亲和力大大降低(ATAD2 的pKd = 5.5/GSK8815 vs. 8.1/GSK8814,ITC法;在通过TR-FRET进行的竞争性配体结合测定中,GSK8815对ATAD2B/ATAD2BBD的pIC50 = 5.5/5.5,对比使用GSK8814的7.3/7.7)。
相对GSK8814效力更低的对照化合物
储存分类代码
11 - Combustible Solids
WGK
WGK 3
历史批次信息供参考:
Paul Bamborough et al.
Angewandte Chemie (International ed. in English), 55(38), 11382-11386 (2016-08-18)
ATAD2 is a cancer-associated protein whose bromodomain has been described as among the least druggable of that target class. Starting from a potent lead, permeability and selectivity were improved through a dual approach: 1) using CF2 as a sulfone bio-isostere
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持